NASDAQ · NVNO
Healthcare · Medical - Devices
$8.20
Up+$0.19 (+2.37%)
Updated Oct 7, 2026, 8:40 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NVNO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
NVNO closed at $8.20 after 21 trading sessions, down 28.63% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $8.01 | $8.47 | $7.96 | $8.20 | 36.78K |
| Oct 5, 2026 | $7.92 | $8.60 | $7.75 | $8.01 | 10.58K |
| Oct 2, 2026 | $8.11 | $8.78 | $7.70 | $8.10 | 24.25K |
| Oct 1, 2026 | $8.82 | $9.41 | $8.01 | $8.04 | 25.19K |
| Sep 30, 2026 | $8.53 | $9.00 | $7.80 | $7.80 | 123.18K |
| Sep 29, 2026 | $8.74 | $8.74 | $8.6243 | $8.625 | 2.06K |
| Sep 28, 2026 | $8.81 | $8.81 | $8.81 | $8.81 | 1.04K |
| Sep 25, 2026 | $8.67 | $8.67 | $8.67 | $8.67 | 440.37 |
| Sep 24, 2026 | $8.61 | $9.09 | $8.61 | $9.09 | 681.93 |
| Sep 23, 2026 | $8.845 | $8.96 | $8.66 | $8.96 | 4.55K |
| Sep 22, 2026 | $8.91 | $9.11 | $8.86 | $9.10 | 9.96K |
| Sep 21, 2026 | $8.84 | $9.1567 | $8.59 | $9.05 | 25.1K |
| Sep 18, 2026 | $8.95 | $9.155 | $8.645 | $8.975 | 7.85K |
| Sep 17, 2026 | $9.19 | $9.4399 | $8.78 | $8.7931 | 4.51K |
| Sep 16, 2026 | $9.4163 | $9.44 | $7.01 | $9.05 | 39.3K |
| Sep 15, 2026 | $9.60 | $9.60 | $9.07 | $9.32 | 29.98K |
| Sep 14, 2026 | $10.24 | $10.32 | $9.28 | $9.38 | 90.91K |
| Sep 11, 2026 | $11.49 | $11.65 | $9.97 | $10.49 | 55.59K |
| Sep 10, 2026 | $11.38 | $11.675 | $11.10 | $11.12 | 60.93K |
| Sep 9, 2026 | $11.4121 | $11.82 | $10.85 | $11.10 | 94.42K |
| Sep 8, 2026 | $11.31 | $11.62 | $11.16 | $11.49 | 4.18K |
The latest Smart Investors Daily articles mentioning NVNO.
Company
Market Activity
Research & News
NVNO research
Company profile and research snapshot.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Oct 2, 2026
Leading venous interventionalist Karen B. Garby, MD, DABVLM, RPhS, to present the enVVe® System, a minimally invasive replacement venous valve currently being evaluated in a U.
Yahoo · Sep 16, 2026
New CEO-led video series provides investors with straight talk, just the facts, with no B. or corporate spinReal answers to what investors need to know about enVVeno and why they need to know itWatch the inaugural episode hereIRVINE, CA / ACCESS Newswire / September 16, 2026 / (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced the launch of "WTF Rob Berman" a new video series that provides the information that investors need to know, in straight talk, with no corporate spin.
Yahoo · Sep 11, 2026
Access the video webcast hereIRVINE, CA / ACCESS Newswire / September 11, 2026 / (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that its pre-recorded presentation from the H. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.
Benzinga · Aug 21, 2026
-SEC Filing
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NVNO.
